BioAge Labs, Inc. BIOA
5.96 USD +0.16 (+2.76%)
At closeNov 3, 2026, 4:01 PM EST
5.96 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
5.58 Day range 6.01
4.81 52-week range 25.96
- YTD
- -54.95%
- 1 year
- -19.68%
Analyst view
Price target (mean) 49.50 +730.5% upside
Now 5.96
- Target (low)
- 23.00
- Target (mean)
- 49.50
- Target (high)
- 73.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.63167 | -0.75 – -0.54 | -0.60 | -5.3% | 1.58M | -34.3% | 6 |
| Next quarter | -0.65612 | -0.85 – -0.53 | -0.56 | -17.2% | 1.54M | -25.0% | 6 |
| Current year | -2.49 | -3.03 – -2.12 | -2.24 | -11.3% | 54.29M | +503.6% | 7 |
| Next year | -2.06 | -3.02 – 1.15 | -2.49 | +17.3% | 35.42M | -34.8% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 27, 2026 | Roth Capital | Initiated | — | Buy |
| May 13, 2026 | BTIG | Initiated | — | Buy |
| Mar 27, 2026 | Needham | Initiated | — | Buy |
| Mar 10, 2026 | Citigroup | Maintained | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | Initiated | — | Outperform |
| Feb 18, 2026 | Jefferies | Upgrade | Hold | Buy |
| Jan 27, 2026 | Piper Sandler | Initiated | — | Overweight |
| Dec 8, 2025 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
| Oct 29, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 22, 2025 | Citigroup | Upgrade | Neutral | Buy |
| Mar 24, 2025 | Citigroup | Maintained | Neutral | Neutral |
| Feb 28, 2025 | William Blair | Initiated | — | Market Perform |
| Dec 9, 2024 | Citigroup | Downgrade | Buy | Neutral |
| Dec 9, 2024 | Jefferies | Downgrade | Buy | Hold |